Rodolfo Giuliani
Rodolfo Giuliani publishes mostly in Psychiatry and Mental health, Neurology and Cellular and Molecular Neuroscience, on topics such as Schizophrenia research and treatment, Parkinson's Disease Mechanisms and Treatments and Treatment of Major Depression.
- World rank
- #3,190,321 of 7,710,434 ranked researchers
- Rank in Italy
- #107,975 of 242,206
- Works
- 19
- Citations
- 837
- Citations per work
- 44.1
What does Rodolfo Giuliani research?
Rodolfo Giuliani's work is mostly in Medicine (52%), Neuroscience (9%), Health Professions (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1156.8%
- Medicine1052.3%
- Health Professions14.5%
- Everything else629.6%
- Life Sciences29.1%
- Neuroscience29.1%
- Social Sciences14.5%
- Psychology14.5%
- 1Psychiatry and Mental health23% of their works
- 2Neurology20% of their works
- 3Cellular and Molecular Neuroscience9% of their works
- 4Pharmacology9% of their works
- 5General Health Professions4% of their works
- 6Clinical Psychology4% of their works
Research topics
- Schizophrenia research and treatment
- Parkinson's Disease Mechanisms and Treatments
- Treatment of Major Depression
- Neurological disorders and treatments
- Neuroscience and Neuropharmacology Research
- Bipolar Disorder and Treatment
- Child and Adolescent Psychosocial and Emotional Development
- Phosphodiesterase function and regulation
Which keywords describe Rodolfo Giuliani's research?
The keywords of their largest research topics: Parkinson's Disease, Antipsychotic Drugs, Neurocognitive Deficits, Treatment-Resistant Depression, a-Synuclein, Depression, Neurodegeneration and Synaptic Plasticity.
- Cyclic Nucleotide Phosphodiesterases
- Prevalence
- GABAergic
- Bipolar Spectrum Disorder
- Deep Brain Stimulation
- Antidepressant
- a-Synuclein
- Neurodegeneration
- Treatment-Resistant Depression
- Antipsychotic Drugs
- Parkinson's Disease
- Neurocognitive Deficits
- Depression
- Synaptic Plasticity
- Neurological Disorders
- Ketamine
- Subthalamic Nucleus
- Emotion Regulation
- Neurotransmission
- Psychopathology
- cAMP Signaling
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 21 words, with their numbers
- Parkinson's Disease92 topics
- Antipsychotic Drugs71 topic
- Neurocognitive Deficits71 topic
- Treatment-Resistant Depression72 topics
- Depression62 topics
- Neurodegeneration61 topic
- Synaptic Plasticity62 topics
- a-Synuclein61 topic
- Neurological Disorders52 topics
- Antidepressant41 topic
- Ketamine41 topic
- Deep Brain Stimulation31 topic
- Subthalamic Nucleus31 topic
- Bipolar Spectrum Disorder21 topic
- Emotion Regulation21 topic
- GABAergic21 topic
- Neurotransmission21 topic
- Prevalence21 topic
- Psychopathology21 topic
- Cyclic Nucleotide Phosphodiesterases11 topic
- cAMP Signaling11 topic
Where does Rodolfo Giuliani work?
Rodolfo Giuliani's main affiliation in the publication record is Newron Pharmaceuticals (Italy), Italy.
How many publications and citations does Rodolfo Giuliani have?
OpenAlex counts 19 works and 837 citations for Rodolfo Giuliani, an h-index of 6, ranking #3,190,321 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Rodolfo Giuliani. Posts are plain text and can be reported.